-
Product Insights
Brain Cancer – Drugs In Development, 2023
Global Markets Direct’s, ‘Brain Cancer - Drugs In Development, 2023’, provides an overview of the Brain Cancer pipeline landscape. The report provides comprehensive information on the therapeutics under development for Brain Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – LB-101 in Cutaneous Squamous Cell Carcinoma (cSCC)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - LB-101 in Cutaneous Squamous Cell Carcinoma (cSCC) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. LB-101 in Cutaneous Squamous Cell Carcinoma (cSCC) Drug...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – LB-101 in Head And Neck Squamous Cell Carcinoma (HNSC)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - LB-101 in Head And Neck Squamous Cell Carcinoma (HNSC) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. LB-101 in Head And Neck Squamous...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – DCSZ-11 in Metastatic Renal Cell Carcinoma
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. DCSZ-11 in Metastatic Renal Cell Carcinoma Drug Details: DCSZ-11 is under development for the treatment...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – LB-101 in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - LB-101 in Solid Tumor report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. LB-101 in Solid Tumor Drug Details: LB-101 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – LB-101 in Non-Small Cell Lung Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - LB-101 in Non-Small Cell Lung Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. LB-101 in Non-Small Cell Lung Cancer Drug Details: LB-101...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – LB-101 in Metastatic Colorectal Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - LB-101 in Metastatic Colorectal Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. LB-101 in Metastatic Colorectal Cancer Drug Details: LB-101 is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – LB-101 in Metastatic Ovarian Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - LB-101 in Metastatic Ovarian Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. LB-101 in Metastatic Ovarian Cancer Drug Details: LB-101 is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – MRNA-1345 in Respiratory Syncytial Virus (RSV) Infections
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - MRNA-1345 in Respiratory Syncytial Virus (RSV) Infections report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. MRNA-1345 in Respiratory Syncytial Virus (RSV) Infections Drug...